GalaGen/Wyeth-Ayerst
This article was originally published in The Tan Sheet
Executive Summary
Enter agreement to develop and commercialize a proprietary ingredient with specific anti-infective properties for use in infant formulas, GalaGen announces Oct. 20. Wyeth will assume financial and oversight responsibilities regarding regulatory compliance and will obtain worldwide rights to use the ingredient in its formulas while Arden Hills, Minn.-based GalaGen will retain certain manufacturing, product development and licensing rights. The anti-infective R&D company is expanding applications for its Proventra brand Natural Immune Components technology; Wyeth-Ayerst distributes private-label infant formulas in the U.S